News
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s ...
In the market’s rapid rise, the portfolio lagged the Russell 2000® Growth Index in Q2. However, the portfolio remains ahead of the benchmark year-to-date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback